证券代码：600998 证券简称：九州通 公告编号：临 2023-079 九州通医药集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 被担保人名称及是否为上市公司关联人：被担保人包括陕西九州通医药有限 公司、河南九州通医药有限公司等 40 家控股子公司（含天津九州通达医药有限 公司、厦门九州通医药有限公司等 17 家全资子公司），不存在关联担保； ● 本次担保金额及已实际提供的担保余额：九州通医药集团股份有限公司（以下 简称"公司"或"九州通集团"）7 月新增担保金额合计 320,705.00 万元，同时解除 担保金额合计 166,214.00 万元。截至 2023 年 7 月 31 日，公司提供担保余额为 2,357,915.00 万元，主要为对控股子公司（含全资子公司）及其下属企业的担保， 不含控股子公司对九州通集团的担保，公司拥有被担保方的控制权，且其现有经 营状况良好，因此担保风险可控； ● 本次担保是否有反担保：有； ● 对外担保逾期的累计数量： ...

证券代码：600998 证券简称：九州通 公告编号：临 2023-049 九州通医药集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开主题：九州通 2022 年度暨 2023 年第一季度业绩说明会 ●会议召开时间：2023 年 5 月 15 日（星期一）下午 13:00-14:30 ●会议召开方式：视频录播结合网络互动 1 二、网络参会方式 （一）为方便广大投资者参与本次业绩说明会，所有投资者可点击以下链接 观看本次业绩说明会并参与互动交流。 1、上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） ●投资者参会平台： 1、上海证券交易所上证路演中心（http://roadshow.sseinfo.com/） 2、中国证券报·中证网路演中心（https://www.cs.com.cn/roadshow/yjsmh/） 3、同花顺路演平台（http://board.10jqka.c ...

证券代码：600998 证券简称：九州通 公告编号：临 2023-047 九州通医药集团股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 5 月 15 日（星期一）下午 13:00-14:30 ●会议召开地点：上海证券交易所上证路演中心（http://roadshow.sseinfo.com /） ●会议召开方式：上证路演中心视频录播和网络互动 ●问题征集：投资者可于 2023 年 5 月 8 日（星期一）至 5 月 12 日（星期五） 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jztdmc@jztey.com 进行提问；公司将在业绩说明会上对投资者普遍关注的问题进 行回答。 九州通医药集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日 发布公司 2022 年年度报告和 2023 年第一季度报告。2022 年，公司在外部环境 复杂多变、行业改革不断深化的背景 ...

Financial Performance - The company's revenue reached 140.424 billion CNY in 2022, a year-on-year increase of 14.72%[4] - The net profit attributable to shareholders, excluding non-recurring items, was 1.734 billion CNY, with a year-on-year growth rate of 23.56%[4] - The cash flow from operating activities improved significantly, totaling 3.986 billion CNY, an increase of 15.24% compared to the previous year[4] - The company's operating revenue for 2022 was ¥140.42 billion, representing a 14.72% increase compared to ¥122.41 billion in 2021[36] - The net profit attributable to shareholders decreased by 14.84% to ¥2.08 billion from ¥2.45 billion in the previous year[36] - The net profit after deducting non-recurring gains and losses increased by 23.56% to ¥1.73 billion, driven by steady growth in pharmaceutical distribution and emerging businesses[38] - The total cash dividend for 2022 amounted to 1,338,303,571.50 RMB, accounting for 64.19% of the net profit attributable to shareholders[16] Business Growth and Expansion - The company plans to add 6,700 new direct and franchise stores in 2023, aiming for a total of over 30,000 stores by 2025[10] - The new product sales are expected to grow by no less than 20% in 2023, with a target of exceeding 15% of total sales by 2025[10] - The company plans to continue expanding its emerging businesses, including pharmaceutical retail and logistics services, to drive future growth[38] - The "Wandian Franchise" initiative has expanded to over 13,000 stores across 31 provinces, with plans to exceed 30,000 stores by 2025[59] - The company has established partnerships with 14 public medical institutions for internet hospitals, achieving a prescription transfer scale of approximately 60 million CNY during the reporting period[64] Digital Transformation and Technology - The company has deepened its digital transformation, with projects like "Smart Medicine" and AI-driven procurement being implemented[9] - The company is actively promoting the "Wanshop Franchise" plan to accelerate the transformation of its business model[51] - The company has developed a comprehensive digital management system for franchise stores, enhancing operational efficiency and service capabilities[60] - The company has launched a digital transformation project focusing on 16 sub-projects to enhance customer experience and empower external business operations[152] - The company has developed 54 patents related to logistics intelligent equipment, including innovations in automated picking technology[144] E-commerce and Online Services - The B2B e-commerce platform generated 11.642 billion CNY in revenue, up 11.20% year-on-year[5] - The retail e-commerce service platform achieved 5.459 billion CNY in revenue, reflecting a growth of 36.46%[5] - The company's B2C e-commerce sales revenue reached nearly 1 billion CNY, with over 27 million C-end users accumulated, representing a 59% year-on-year growth[61] - The "Mi Health" service platform has over 400,000 paid users and processed over 630,000 prescription transfer orders, with a total insurance fulfillment amount of 250 million CNY, marking a 2,759% increase in service revenue from the previous year[62] - The company achieved an annual revenue of 11.642 billion CNY from the Yaojiu B2B e-commerce platform, accounting for 8.30% of total revenue, with over 400,000 registered users and 350,000 active users[53] Supply Chain and Logistics - The company has established a "trillion-level" pharmaceutical supply chain service platform, integrating "pharmaceutical distribution + logistics + product promotion" as a comprehensive service model[13] - The company operates over 141 pharmaceutical logistics centers and distribution points across 31 provincial capitals and 110 prefecture-level cities, with a total building area exceeding 4.2 million square meters[68] - The logistics integration of Bb/BC has been implemented in 12 companies, aiming for full coverage of this capability in the next three years, with a daily collection rate exceeding 99%[65] - The logistics supply chain solutions business has achieved a peak daily order volume of 250,000 since the launch of the first BC integrated warehouse in Hangzhou, with a monthly peak of 5 million orders and an outbound accuracy rate of 99.999%[71] - The company has developed a unique pharmaceutical cold chain logistics product called "Jiulian Tong," which includes three main components: storage, transportation, and last-mile delivery[142] Corporate Governance and Social Responsibility - The board proposed a cash dividend of 5 RMB per 10 shares (including tax) and a capital reserve conversion of 4.9 shares for every 10 shares, increasing the total share capital to 2,768,251,909 shares[15] - The company donated nearly 30 million CNY in various forms, including emergency medical supplies and educational support, demonstrating its commitment to social responsibility[76] - The company donated over 2.62 million CNY worth of emergency medicines to support local pandemic control efforts in several targeted counties[78] Market Trends and Regulatory Environment - The pharmaceutical circulation market in China reached a total sales volume of 260.64 billion yuan, with a year-on-year growth of 8.5%, indicating an acceleration in market growth[99] - The government has relaxed restrictions on online first consultations for common and chronic diseases, which is expected to accelerate the growth of the Internet healthcare sector[89] - The national strategy includes incorporating eligible Internet medical services into medical insurance payment coverage, which will further support the growth of Internet healthcare services[88] - The introduction of supportive policies for public REITs since 2020 has created significant growth opportunities in the public REITs market, enhancing the investment landscape[94] Research and Development - Research and development expenses decreased by 8.49% to ¥178.39 million from ¥194.94 million in the previous year[198] - The company is focusing on expanding its digital health management capabilities and enhancing its product development through a new ecosystem model[197] - The company aims to reduce birth defect rates by 1% through the application of genomic testing technologies in clinical settings[197]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 42,092,541,357, representing a year-on-year increase of 19.75%[4] - Net profit attributable to shareholders was CNY 561,172,724.88, up 24.06% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 573,181,108.58, reflecting a growth of 20.10% year-on-year[4] - The basic earnings per share for the period was CNY 0.29, an increase of 26.09% from the previous year[5] - Total operating revenue for Q1 2023 reached RMB 42.09 billion, a 19.7% increase from RMB 35.15 billion in Q1 2022[23] - Net profit for Q1 2023 was RMB 598.44 million, up 25.1% from RMB 478.21 million in Q1 2022[24] - Operating profit for Q1 2023 was RMB 729.92 million, representing a 26.2% increase compared to RMB 578.34 million in Q1 2022[24] - The company reported a total comprehensive income of RMB 592.90 million for Q1 2023, compared to RMB 501.73 million in Q1 2022[25] - Basic earnings per share for Q1 2023 were RMB 0.29, an increase from RMB 0.23 in Q1 2022[25] Asset and Liability Management - The total assets at the end of the reporting period amounted to CNY 96,415,023,973.10, a 4.49% increase from the end of the previous year[5] - The total current assets increased to approximately 79.57 billion yuan, up from 75.66 billion yuan in the previous period, reflecting a growth of about 5.3%[20] - The company's total assets reached approximately 96.42 billion yuan, compared to 92.27 billion yuan in the previous period, marking an increase of about 4.6%[22] - Short-term borrowings rose to approximately 12.58 billion yuan, up from 11.49 billion yuan, indicating an increase of about 9.5%[21] - The total liabilities increased to approximately 67.21 billion yuan, compared to 63.59 billion yuan, reflecting a growth of about 5.1%[21] - The company's equity attributable to shareholders reached approximately 25.20 billion yuan, up from 24.64 billion yuan, indicating an increase of about 2.3%[21] Cash Flow Analysis - The company's cash flow from operating activities showed a net outflow of CNY 3,021,589,444.65, a decrease of 14.19% year-on-year[4] - Cash flow from operating activities in Q1 2023 was RMB 34.09 billion, an increase from RMB 29.35 billion in Q1 2022[26] - The net cash flow from operating activities was -3,021,589,444.65 RMB, compared to -2,646,124,039.84 RMB in the previous year, indicating a decline of approximately 14.2%[27] - Total cash outflow from operating activities amounted to 37,112,112,985.91 RMB, an increase of 15.5% from 31,995,646,766.24 RMB year-over-year[27] - The net cash flow from investing activities was -177,134,497.43 RMB, a significant decrease from 1,652,589,306.34 RMB in the previous year[27] - Cash inflow from financing activities totaled 8,405,285,106.46 RMB, down 14.1% from 9,782,021,294.34 RMB year-over-year[27] - The net cash flow from financing activities was 1,461,533,978.13 RMB, compared to -249,314,751.27 RMB in the previous year, showing a positive turnaround[27] - The ending balance of cash and cash equivalents was 5,922,400,416.67 RMB, slightly up from 5,839,027,202.15 RMB year-over-year[28] Business Growth and Strategy - The revenue from the brand promotion business grew by 33.99%, with gross profit increasing by 92.78% compared to the previous year[6] - The revenue from the pharmaceutical retail business surged by 62.24%, with gross profit rising by 68.33% year-on-year[6] - The revenue from third-party logistics increased by 36.99%, with gross profit up by 55.75% compared to the same period last year[6] - The company has exceeded 13,000 self-operated and franchised pharmacies under the "Ten Thousand Store Franchise" plan, covering 1,122 cities across 31 provinces, with a target of over 30,000 stores by 2025[18] - The "Mi Health" service platform has surpassed 400,000 paying users, with over 630,000 prescription transfer orders and an insurance fulfillment amount of 250 million yuan[18] - The company has launched six integrated "BC warehouses" in Guangdong, Shanghai, Jiangsu, Hubei, Zhejiang, and Tianjin, aiming for full coverage of "Bb/BC warehouse integration" capabilities in the next three years[18] - The company has completed the "Bb integration" transformation for 12 logistics companies, achieving "zero inventory" for clients and sharing 100,000 product specifications[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,486, with the top ten shareholders holding a combined 56.85% of shares[11] - Shanghai Hongkang Industrial Investment Co., Ltd. holds 404,441,118 shares, accounting for 21.58% of total shares, with 240,240,000 shares pledged[11] - Lion Dragon International Group (Hong Kong) Limited holds 213,894,000 shares, representing 11.41% of total shares[11] - The top ten preferred shareholders hold a total of 20 million shares, with China Orient Asset Management Co., Ltd. holding 5 million shares, accounting for 25%[14] - The top ten shareholders include several entities with pledged shares, indicating a potential risk in shareholder stability[11] Future Initiatives - The company plans to initiate a public REITs issuance for pharmaceutical logistics and warehousing assets, aiming to raise up to 3 billion RMB[17] - The REITs project is expected to enhance the company's financial metrics and improve asset liquidity, reducing reliance on traditional debt financing[17] - The company is actively responding to national policy initiatives by launching the REITs project, which is expected to positively impact its market presence[17] - The company aims to activate over 3 million square meters of pharmaceutical logistics and warehousing assets through the REITs initiative[17]